한글목차

세계 카르비도파 시장은 2024년 4억 7,512만 달러로 평가되었고, 2030년에는 6억 8,965만 달러에 달할 것으로 예상되며, 예측 기간 동안 7.99%의 연평균 성장률(CAGR)을 보일 것으로 예측됩니다.

시장 성장의 원동력은 파킨슨병 및 기타 신경계 질환 관련 치료에 대한 전 세계 수요 증가입니다.

칼비도파는 레보도파의 생체 이용률과 치료 효과를 향상시킴으로써 병용요법(특히 레보도파와의 병용요법)에서 중요한 역할을 하고 있습니다. 전 세계 인구의 고령화와 파킨슨병 발병률 증가로 인해 효과적이고 장기적인 치료 옵션에 대한 수요가 증가하면서 시장 확대가 가속화되고 있습니다.

경쟁 구도으로는 다국적 제약기업과 지역 제조업체들이 상황에 맞는 치료제의 개발, 생산, 상업화에 적극 나서고 있습니다. 연구개발에 대한 막대한 투자는 특히 서방화 기술 및 방출 제어 기술을 통한 약물 제제의 최적화에 중점을 두어 치료성적의 향상과 부작용의 감소를 도모하고 있습니다. 전략적 파트너십, 합병, 의료기관과의 제휴는 시장 내 기술 혁신과 경쟁력을 더욱 강화하고 있습니다.

주요 시장 성장 촉진요인

세계 헬스케어 부문 확대

주요 시장 이슈

부작용과 안전에 대한 우려

주요 시장 동향

병용요법 도입 증가

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 COVID-19가 세계의 카르비도파 시장에 미치는 영향

제5장 세계의 카르비도파 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율과 예측
  • 판매채널별(직접, 간접)
  • 용도별(특발성 파킨슨병, 뇌염 후 파킨슨병, 증후성 파킨슨병, 기타)
  • 지역별
  • 기업별(2024년)
• 시장 맵

제6장 북미의 카르비도파 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 북미 : 국가별 분석
  • 미국
  • 멕시코
  • 캐나다

제7장 유럽의 카르비도파 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 프랑스
  • 독일
  • 영국
  • 이탈리아
  • 스페인

제8장 아시아태평양의 카르비도파 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 한국
  • 일본
  • 호주

제9장 남미의 카르비도파 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 카르비도파 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트(UAE)

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 인수합병(M&A)
• 제품 출시
• 최근 동향

제13장 세계의 카르비도파 시장 : SWOT 분석

제14장 Porter의 Five Forces 분석

• 업계내 경쟁
• 신규 참여 가능성
• 공급업체의 힘
• 고객의 힘
• 대체품의 위협

제15장 경쟁 구도

• Smruthi Organics Ltd.
• Zhejiang Yefeng Pharmaceutical Co., Ltd
• Divi's Laboratories Limited
• GreenSyn Life Science
• Xi'an D-Sung Biotechnology Co., Ltd.
• Hetero Drugs limited
• Hangzhou Dingyan Chem Co.,Ltd
• Zhejiang Yongtai Chiral Pharmaceutical Technology Co., Ltd.
• Xi'an Yihui Bio-technology Co., Ltd
• Hanhong Medicine Technology(hubei) co. Ltd

제16장 전략적 제안

제17장 리서치사에 대해 & 면책사항

영문목차

Global Carbidopa Market was valued at USD 475.12 million in 2024 and is projected to reach USD 689.65 million by 2030, expanding at a compound annual growth rate (CAGR) of 7.99% during the forecast period. Market growth is being driven by the rising global demand for treatments related to Parkinson's disease and other neurological conditions.

Carbidopa plays a critical role in combination therapies-most notably with levodopa-by increasing levodopa's bioavailability and therapeutic efficacy. As the global population continues to age and the incidence of Parkinson's disease rises, the demand for effective, long-term treatment options is accelerating market expansion.

The competitive landscape includes both multinational pharmaceutical companies and regional manufacturers actively engaged in the development, production, and commercialization of carbidopa-based therapies. Significant investments in research and development are focused on optimizing drug formulations, particularly through extended-release and controlled-release technologies, to enhance treatment outcomes and reduce adverse effects. Strategic partnerships, mergers, and collaborations with healthcare institutions are further driving innovation and competitive positioning within the market.

Key Market Drivers

Expansion of the Global Healthcare Sector

The global growth of the healthcare industry is a major driver for the carbidopa market. Healthcare accounts for a significant share of GDP in developed economies-surpassing 10% in many countries. For instance, in the United States, healthcare expenditure reached USD 4.3 trillion in 2021, equating to USD 12,914 per capita, reflecting a 2.7% year-over-year increase.

Carbidopa is widely used in the treatment of Parkinson's disease and related neurodegenerative conditions. As healthcare infrastructure improves and demand for chronic disease management rises, carbidopa's role as an essential pharmaceutical agent has become increasingly prominent.

Key Market Challenges

Side Effects and Safety Concerns

Despite its clinical value, one of the primary challenges hindering market growth is the range of side effects associated with carbidopa-based therapies. While the combination of carbidopa and levodopa remains a cornerstone in Parkinson's disease treatment, patients often experience side effects such as nausea, dizziness, orthostatic hypotension, and dyskinesia. These can significantly impact quality of life and treatment adherence.

Moreover, long-term use may lead to motor fluctuations, characterized by alternating "on" periods-when the medication is effective-and "off" periods-when symptoms return. These complications can make disease management more difficult and reduce the effectiveness of therapy over time, thereby posing a barrier to wider market adoption.

Key Market Trends

Rising Adoption of Combination Therapies

A notable trend in the carbidopa market is the growing use of combination therapies, particularly with levodopa. The carbidopa-levodopa pairing remains the gold standard for managing motor symptoms of Parkinson's disease. Furthermore, newer formulations such as the levodopa/carbidopa/entacapone triple combination infusion-already launched in select European markets-are gaining traction. Early feedback indicates that patients can transition from traditional jejunal levodopa infusion to this novel therapy with relative ease.

Key Market Players

• Smruthi Organics Ltd.
• Zhejiang Yefeng Pharmaceutical Co., Ltd
• Divi's Laboratories Limited
• GreenSyn Life Science
• Xi'an D-Sung Biotechnology Co., Ltd.
• Hetero Drugs limited
• Hangzhou Dingyan Chem Co.,Ltd
• Zhejiang Yongtai Chiral Pharmaceutical Technology Co., Ltd.
• Xi'an Yihui Bio-technology Co., Ltd
• Hanhong Medicine Technology (hubei) co. Ltd

Report Scope

In this report, the Global Carbidopa Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Carbidopa Market, By Sales Channel:

• Direct
• Indirect

Carbidopa Market, By End Use:

• Idiopathic Parkinson Disease
• Postencephalitic Parkinsonism
• Symptomatic Parkinsonism
• Others

Carbidopa Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Carbidopa Market.

Available Customizations:

Global Carbidopa Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Carbidopa Market

5. Global Carbidopa Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Sales Channel (Direct, Indirect)
  • 5.2.2. By End Use (Idiopathic Parkinson Disease, Postencephalitic Parkinsonism, Symptomatic Parkinsonism, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Carbidopa Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Sales Channel
  • 6.2.2. By End Use
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Carbidopa Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Sales Channel
      • 6.3.1.2.2. By End Use
  • 6.3.2. Mexico Carbidopa Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Sales Channel
      • 6.3.2.2.2. By End Use
  • 6.3.3. Canada Carbidopa Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Sales Channel
      • 6.3.3.2.2. By End Use

7. Europe Carbidopa Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Sales Channel
  • 7.2.2. By End Use
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Carbidopa Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Sales Channel
      • 7.3.1.2.2. By End Use
  • 7.3.2. Germany Carbidopa Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Sales Channel
      • 7.3.2.2.2. By End Use
  • 7.3.3. United Kingdom Carbidopa Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Sales Channel
      • 7.3.3.2.2. By End Use
  • 7.3.4. Italy Carbidopa Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Sales Channel
      • 7.3.4.2.2. By End Use
  • 7.3.5. Spain Carbidopa Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Sales Channel
      • 7.3.5.2.2. By End Use

8. Asia Pacific Carbidopa Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Sales Channel
  • 8.2.2. By End Use
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Carbidopa Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Sales Channel
      • 8.3.1.2.2. By End Use
  • 8.3.2. India Carbidopa Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Sales Channel
      • 8.3.2.2.2. By End Use
  • 8.3.3. South Korea Carbidopa Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Sales Channel
      • 8.3.3.2.2. By End Use
  • 8.3.4. Japan Carbidopa Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Sales Channel
      • 8.3.4.2.2. By End Use
  • 8.3.5. Australia Carbidopa Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Sales Channel
      • 8.3.5.2.2. By End Use

9. South America Carbidopa Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Sales Channel
  • 9.2.2. By End Use
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Carbidopa Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Sales Channel
      • 9.3.1.2.2. By End Use
  • 9.3.2. Argentina Carbidopa Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Sales Channel
      • 9.3.2.2.2. By End Use
  • 9.3.3. Colombia Carbidopa Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Sales Channel
      • 9.3.3.2.2. By End Use

10. Middle East and Africa Carbidopa Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Sales Channel
  • 10.2.2. By End Use
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Carbidopa Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Sales Channel
      • 10.3.1.2.2. By End Use
  • 10.3.2. Saudi Arabia Carbidopa Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Sales Channel
      • 10.3.2.2.2. By End Use
  • 10.3.3. UAE Carbidopa Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Sales Channel
      • 10.3.3.2.2. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Carbidopa Market: SWOT Analysis

14. Porters Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Smruthi Organics Ltd.
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Zhejiang Yefeng Pharmaceutical Co., Ltd
• 15.3. Divi's Laboratories Limited
• 15.4. GreenSyn Life Science
• 15.5. Xi'an D-Sung Biotechnology Co., Ltd.
• 15.6. Hetero Drugs limited
• 15.7. Hangzhou Dingyan Chem Co.,Ltd
• 15.8. Zhejiang Yongtai Chiral Pharmaceutical Technology Co., Ltd.
• 15.9. Xi'an Yihui Bio-technology Co., Ltd
• 15.10. Hanhong Medicine Technology (hubei) co. Ltd

16. Strategic Recommendations

17. About Us & Disclaimer